Canton Strategic Holdings, Inc. (CNTN) Fair Value & Analysis

Healthcare · US · Market cap $234M

Below-average quality, trading 32% below our fair value.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

• The large discount to fair value meets weak quality (16/100). That raises the risk this is a value trap rather than a bargain.
• The price is below even our cautious bear case ($2.42). The market is more pessimistic than our downside scenario.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
• A fairly wide model range ($2.42 to $4.85) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 15, 2026.

How to read this chart

55‑month range $1.05 – $1,538 · fair‑value band $2.42 – $4.85 · the $2.22 price screens below the $3.25 fair value. Dashed = 300-day average. As of Jul 15, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Canton Strategic Holdings, Inc. (CNTN) currently trades at $2.22, while our model-based Fair Value estimate is $3.25, implying the stock looks roughly 46.3% undervalued today. The Quality Score stands at 16/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.

It earns a return on equity of -34.4%. The balance sheet holds a net cash position of $17.0M. Fundamentals as of Jul 15, 2026

Our scenario range runs from $2.42 (bear case) to $4.85 (bull case); at $2.22, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 76% below its 52-week high and 105% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -59% fair-value upside, at 46%, CNTN screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

Canton Strategic Holdings, Inc. engages in the institutional blockchain adoption and digitization of financial markets in the United States. It operates in two segments, Digital Asset Treasury and Clinical Stage Bio-technology.

Full company description

Canton Strategic Holdings, Inc. engages in the institutional blockchain adoption and digitization of financial markets in the United States. It operates in two segments, Digital Asset Treasury and Clinical Stage Bio-technology. The company is involved in the operation of Canton Coin-centric digital asset treasury strategies, including validator operations and network participation; application support and strategic investments; collaboration and ecosystem advancement; capital raising and treasury expansion; token management - locking, lending, and options; Canton Foundation; and governance and risk management. It also researches and develops GV104, a buccal film formulation of nalmefene for the treatment of respiratory depression and prophylactic protection against synthetic opioid exposure in military and first responders; and GV023, an oral anti-tumor necrosis factor-alpha monoclonal antibody that addresses critical limitation of IV gold standard for the treatment of repeated intravenous infusions. The company was formerly known as Tharimmune, Inc. and changed its name to Canton Strategic Holdings, Inc. in February 2026. Canton Strategic Holdings, Inc. was incorporated in 2017 and is headquartered in Red Bank, New Jersey.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Canton Strategic Holdings, Inc. reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$35.9M in FY2025.

Watch CNTN: get an alert when its fair value changes →

Peer Group

Biotechnology · 639 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Biotechnology median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Discover undervalued stocks

Pick a strategy and jump into the live analysis with that exact screen applied.

Discover tools

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.